BACKGROUND: Studies among individuals ages ≥65 years have found a moderately higher relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared with standard-dose (SD) products for most seasons. Studies during the A(H3N2)-dominated 2017-2018 season showed slightly higher RVE for the cell-cultured vaccine compared with SD egg-based vaccines. We investigated the RVE of influenza vaccines among Medicare beneficiaries ages ≥65 years during the 2018-2019 season. METHODS: This is a retrospective cohort study using inverse probability of treatment weighting and Poisson regression to evaluate RVE in preventing influenza hospital encounters. RESULTS: Among 12 777 214 beneficiaries, the egg-based adjuvanted (RVE, 7.7%; 95% confidence interval [CI], 3.9%-11.4%) and HD (RVE, 4.9%; 95% CI, 1.7%-8.1%) vaccines were marginally more effective than the egg-based quadrivalent vaccines. The cell-cultured quadrivalent vaccine was not significantly more effective than the egg-based quadrivalent vaccine (RVE, 2.5%; 95% CI, -2.4% to 7.3%). CONCLUSIONS: We did not find major effectiveness differences between licensed vaccines used among the elderly during the 2018-2019 season. Consistent with prior research, we found that the egg-based adjuvanted and HD vaccines were slightly more effective than the egg-based quadrivalent vaccines. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Studies among individuals ages ≥65 years have found a moderately higher relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared with standard-dose (SD) products for most seasons. Studies during the A(H3N2)-dominated 2017-2018 season showed slightly higher RVE for the cell-cultured vaccine compared with SD egg-based vaccines. We investigated the RVE of influenza vaccines among Medicare beneficiaries ages ≥65 years during the 2018-2019 season. METHODS: This is a retrospective cohort study using inverse probability of treatment weighting and Poisson regression to evaluate RVE in preventing influenza hospital encounters. RESULTS: Among 12 777 214 beneficiaries, the egg-based adjuvanted (RVE, 7.7%; 95% confidence interval [CI], 3.9%-11.4%) and HD (RVE, 4.9%; 95% CI, 1.7%-8.1%) vaccines were marginally more effective than the egg-based quadrivalent vaccines. The cell-cultured quadrivalent vaccine was not significantly more effective than the egg-based quadrivalent vaccine (RVE, 2.5%; 95% CI, -2.4% to 7.3%). CONCLUSIONS: We did not find major effectiveness differences between licensed vaccines used among the elderly during the 2018-2019 season. Consistent with prior research, we found that the egg-based adjuvanted and HD vaccines were slightly more effective than the egg-based quadrivalent vaccines. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Constantina Boikos; Lauren Fischer; Dan O'Brien; Joe Vasey; Gregg C Sylvester; James A Mansi Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079
Authors: G K Balasubramani; Won Suk Choi; Mary Patricia Nowalk; Richard K Zimmerman; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Michael L Jackson; Lisa A Jackson; Jessie R Chung; Sarah Spencer; Alicia M Fry; Manish Patel; Brendan Flannery Journal: Vaccine Date: 2020-08-13 Impact factor: 4.169
Authors: Michele A Kohli; Michael Maschio; Joaquin F Mould-Quevedo; Mansoor Ashraf; Michael F Drummond; Milton C Weinstein Journal: Vaccines (Basel) Date: 2021-06-04
Authors: Constantina Boikos; Mahrukh Imran; Van Hung Nguyen; Thierry Ducruet; Gregg C Sylvester; James A Mansi Journal: Open Forum Infect Dis Date: 2021-04-02 Impact factor: 3.835